To observe the efficacy of traditional Chinese medicine in treating the advanced non-small cell lung cancer (NSCLC) after chemotherapy. Methods： A clinical retrospective analysis of the patients with advanced NSCLC was done. Main out come meansures：： Efficacy evaluation, Time to disease progression (TTP), One year survival rate, Overall survival (OS). Results： After four cycles of treatment, there were 62 (84.9%) CR + PR + SD cases in the chemotherapy group while 62 cases (82.7%) in the Chinese medicine treatment group, but the difference was not statistically significant (P=0.554). The stratified statistics for the two groups excluding PD patients came out that the median TTP of chemotherapy group was 5.0 months and 4.0 months of the Chinese medicine group with no statistically significant difference (P= 0.183). One year survival rate of chemotherapy group was 57.5%, and it was 60.0% of Chinese medicine group, the difference was not statistically significant (0.952). The chemotherapy group’s median OS was 17 months, traditional Chinese medicine’s OS was 16 months, the difference was not statistically significant (P= 0.715). Conclusion： For the advanced NSCLC patients whose efficacy evaluation of pre-treatment was stable, the choice of Chinese medicine treatment would show a positive role in maintaining tumor size and decelerating the disease progression. And the effect is not inferior to continue chemotherapy.